ArticleMolecules (Basel, Switzerland)2023
Effects of Losartan, Atorvastatin, and Aspirin on Blood Pressure and Gut Microbiota in Spontaneously Hypertensive Rats.
Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Angiotensin converting enzyme inhibitors and angiotensin receptor blockers impact on the gut microbiome: a systematic review.Frontiers in endocrinology · 2025Pooled it
- Effect of aspirin on blood pressure in hypertensive patients: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- Intervening at the microbial crossroads: targeting inflammation across the oral-gut-reproductive microbiome crosstalk in atherosclerosis.Antonie van Leeuwenhoek · 2026Review
- Targeting the Th17/Treg axis: from immunological insights to therapeutic avenues in atherosclerosis.Frontiers in immunology · 2026Review
- Negative association between body roundness index and constipation: insights from NHANES.Journal of health, population, and nutrition · 2025Article
- Interplay of gut microbiota in Kawasaki disease: role of gut microbiota and potential treatment strategies.Future microbiology · 2025Review
- Effects of different antiplatelet therapy drugs on platelet activation and platelet-leukocyte aggregate formation in early septic ARDS.BMC pharmacology & toxicology · 2025Article
- Gut microbiome and inflammation in cardiovascular drug response: trends in therapeutic success and commercial focus.Inflammopharmacology · 2025Review
- Gut microbiota-derived short-chain fatty acids mediate the antifibrotic effects of traditional Chinese medicine in diabetic nephropathy.Frontiers in endocrinology · 2025Review
- HFD aggravated the arthritis and atherosclerosis by altering the intestinal status and gut microbiota.Molecular medicine (Cambridge, Mass.) · 2024Article
- Gut microbiome related to metabolic diseases after moderate-to-vigorous intensity exercise.Journal of exercise science and fitness · 2024Article
- Dynamic gut microbiome-metabolome in cationic bovine serum albumin induced experimental immune-complex glomerulonephritis and effect of losartan and mycophenolate mofetil on microbiota modulation.Journal of pharmaceutical analysis · 2024Article
- Gut microbiota: a potential new regulator of hypertension.Frontiers in cardiovascular medicine · 2024Review
- Analysis of Factors Associated with Constipation in the Population with Obesity: Evidence from the National Health and Nutrition Examination Survey.Obesity facts · 2024Article
- Sexual Dimorphic Interplays Between Gut Microbiota and Antihypertensive Drugs.Current hypertension reports · 2023Review
- Gut Microbiota and Microbial Metabolism in Early Risk of Cardiometabolic Disease.Circulation research · 2023Review
- Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats.Molecules (Basel, Switzerland) · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Many studies have shown that alterations in the gut microbiota are associated with hypertension. Our study aimed to observe the characteristics of the gut microbiota in hypertension and to further explore whether drug molecules can play a therapeutic role in hypertension by interfering with the gut microbiota. We evaluated the differences in the composition of the gut microbiota in spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY). Meanwhile, three first-line cardiovascular disease (CVD) drugs, losartan, atorvastatin, and aspirin, were used to treat the SHR in order to observe their effects on the gut microbiota in SHR. The 16S rDNA results showed that the diversity and richness of the gut microbiota in SHR were significantly reduced compared with that of the WKY, the Firmicutes/Bacteroidetes ratio was increased, the abundances of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.